Mizuho
-
Mizuho International has hired a banker from Standard Chartered to help build its nascent FIG business in Europe.
-
Mizuho Financial Group is to establish a consolidated vanilla derivatives platform in London by combining Mizuho Capital Markets, a derivatives business, with Mizuho International, its securities and investment banking arm.
-
Mizuho Financial Group has appointed Jaj Singh as executive director and head of financials research for Asia ex-Japan, poaching him from Nomura.
-
Allocations are out for a HK$8bn ($1bn) fundraising for Lifestyle International Holdings, which operates Sogo department stores.
-
Kookmin Bank opted for an unusual three year bond this week to diversify its funding avenues. The bond found strong interest from offshore accounts eager to get their hands on the new deal, allowing the lender to price inside fair value.
-
South Korea’s Kookmin Bank and Indian’s Glenmark Pharmaceuticals ventured out to the dollar debt market on Monday with their respective bonds.
-
Mizuho has recently seen the departures of two bankers in its loans team in Singapore — one each from origination and distribution.
-
Israeli-American pharmaceutical company Teva ripped through a severely undersupplied European corporate bond market this week, making savage price cuts on all three tranches of a €4bn trade that still ground tighter in secondary markets. Ross Lancaster reports.
-
Teva Pharmaceuticals had the corporate dollar market in its thrall this week as it took advantage of US corporate earnings blackouts to print a $15bn M&A blockbuster that attracted nearly $70bn worth of orders.
-
Teva completed the final leg of the bond financing for its acquisition of Allergan's generic drugs business on Thursday, issuing a Sfr1bn ($1bn) triple tranche Swiss franc deal.
-
The UK’s largest dental company Mydentist on Thursday launched a £425m bond to refinance all of its debt, becoming the first high yield sterling deal since the country voted to leave the European Union.
-
Israeli-American pharmaceutical company Teva made a swift entry into the European investment grade corporate bond market on Wednesday, winning an order book to rival AB-InBev’s €13.25bn record breaker.